TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00462332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Induction therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplant
Description: Post-induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Post-induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Post-induction therapy
Study: NCT02867878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Study: NCT04506229

Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms

Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms
Study: NCT00723736

Intervention type: DRUG
Intervention: Desloratadine
Description: 2.5 ml (1.25 mg) once daily
Study: NCT03366623

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hospital clown
Description: Presence of the hospital clown

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No hospital clown intervention
Description: Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
Study: NCT01340638

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cookgas mask
Description: This group will be assigned to use cookgas mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA mask
Description: LMA mask
Study: NCT03865264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery Enhancement Program
Description: Behavioral, nutritional, physical and opioid-reduction pain medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery Enhancement Program
Description: Behavioral, nutritional, physical and opioid-reduction pain medication
Study: NCT05187468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: 1000 pulses at 60 mj, 10 Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: 2000 pulses at 60 mj, 10 Hz

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy, Massage, Heat pack
Description: Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
Study: NCT04268290

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Single incision plus one port laparoscopic surgery
Description: SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
Study: NCT03075410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
Study: NCT02652923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid; Perflubutane for Injection
Description: subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid; Perflubutane for Injection
Description: subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
Study: NCT00628264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP214
Description: Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
Study: NCT03743467

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical evaluation of vision and eye tests
Description: * VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical evaluation of vision and eye tests
Description: * VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical evaluation of vision and eye tests
Description: * VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer
Study: NCT04307251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navio™ Robotics-assisted Surgical System, LEGION Total Knee System
Description: Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional, LEGION Total Knee System
Description: Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
Study: NCT02377141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Band Ligation
Description: Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Band Ligation
Description: Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular Intrahepatic Porto-Systemic Stent Shunt
Description: Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
Study: NCT01074216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)
Description: Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
Study: NCT02769377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breeze2 glucometer
Description: Breeze2 glucometer for self-monitoring of blood glucose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breeze2 glucometer
Description: Breeze2 glucometer for self-monitoring of blood glucose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breeze2 glucometer and H2
Description: Breeze2 glucometer and Health2Sync Mobile App for data transfer
Study: NCT02757027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Crystalloid
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous HES
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT02119845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular AVF (EndoAVF)
Description: The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
Study: NCT04646954

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Host DNA methylation testing
Description: Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cervical cytology and/or high-risk human papillomavirus assays
Description: Cervical cytology and/or high-risk human papillomavirus assays
Study: NCT01374373

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Epoetin alfa
Description: Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
Study: NCT04304573

Intervention type: DIAGNOSTIC_TEST
Intervention: Total serum calcium blood test
Description: Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.

Intervention type: DIAGNOSTIC_TEST
Intervention: Total serum calcium blood test
Description: Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
Study: NCT02925013

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling for lipid profile

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for lipid profile

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary- Normal western diet
Description: Normal western diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary- Normal western diet
Description: Normal western diet
Study: NCT00681785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparine (Fragmin)
Description: transurethrals surgery with and without dalteparine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalteparine (Fragmin)
Description: transurethrals surgery with and without dalteparine
Study: NCT01585987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive care (BSC)
Study: NCT00309296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation
Description: This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation
Description: This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
Study: NCT01998087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Description: A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding support
Description: A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
Study: NCT02594605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Flap Surgery
Description: Only Conventional Flap Surgery treatment the bone loss limitedly.
Study: NCT01759407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Study: NCT02377804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel needles (0.3mm x 50mm)
Study: NCT01457547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)
Description: Three doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)
Description: Three doses administered intramuscularly
Study: NCT00556387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
Study: NCT00646633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture and patient education
Description: Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
Study: NCT02083354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
Study: NCT04684888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visumax Femto-flap
Description: Under topical anesthesia \[Tetracaine eye drop 0.5%\]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy \[Carl Zeiss, Meditec, Germany\]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sub Bowman's keratomileusis (SBK)-flap
Description: Under topical anesthesia \[Tetracaine eye drop 0.5%\] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~.
Study: NCT01679314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlphaCore device
Description: Each study group will go under the same treatment regimen and assessments.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AlphaCore device
Description: Each study group will go under the same treatment regimen and assessments.
Study: NCT01615120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 125 mg
Description: One 125 mg tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 250 mg
Description: two 125 mg tablets once daily
Study: NCT03706755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine: 1mcg/kg
Description: intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 0,5mcg/kg
Description: intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
Study: NCT03614650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: engineered immune cells
Description: Engineered immune effector cells (EIE)
Study: NCT02869152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of 99mTc-sulfur colloid
Description: Radiotracer injection around the rectal tumor for SLN mapping with gamma probe